J Patrick McGovren Selected Research

edotecarin (J 107088)

1/2007	A phase I study of the safety and pharmacokinetics of edotecarin (J-107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors.
8/2006	Phase I and pharmacokinetic study of edotecarin, a novel topoisomerase I inhibitor, administered once every 3 weeks in patients with solid tumors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

J Patrick McGovren Research Topics

Disease

3	Neoplasms (Cancer) 01/2007 - 06/2006
1	Breast Neoplasms (Breast Cancer) 05/2011
1	Sepsis (Septicemia) 06/2006
1	Neutropenia 04/2004
1	Colorectal Neoplasms (Colorectal Cancer) 04/2004

Drug/Important Bio-Agent (IBA)

3	Pharmaceutical PreparationsIBA 01/2007 - 06/2006
2	edotecarin (J 107088)IBA 01/2007 - 08/2006
2	Topoisomerase I InhibitorsIBA 01/2007 - 08/2006
2	Irinotecan (Camptosar)FDA LinkGeneric 06/2006 - 04/2004
2	BilirubinIBA 06/2006 - 04/2004
1	Dexrazoxane (Zinecard)FDA LinkGeneric 05/2011
1	Cardiotonic Agents (Cardiac Stimulants)IBA 05/2011
1	Doxorubicin (Adriamycin)FDA LinkGeneric 05/2011
1	trioctyl phosphine oxide (TOPO)IBA 01/2007
1	Type I DNA Topoisomerases (Topoisomerase I)IBA 01/2007
1	Alanine Transaminase (SGPT)IBA 06/2006
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 06/2006

Therapy/Procedure

1	Therapeutics 01/2007
1	Drug Therapy (Chemotherapy) 04/2004